Toxicities Associated With CAR-Modified T Cell Therapy

February 19, 2015
Jae Park, MD

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.

Clinical Pearls

Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.

  • There are unique toxicities associated with CAR-modified T cell therapy, such as cytokine release syndrome.
  • Cytokine release syndrome can cause a patient to experience fever, low blood pressure, and breathing problems.
  • There are now ways for a physician to predict the occurrence and severity of cytokine release syndrome.
  • IL-6 receptor inhibitors or steroids can effectively manage cytokine release syndrome.